Celcuity (CELC) Stock Forecast & Price Target

Celcuity is favored fundamentally because gedatolisib, a differentiated IV PI3K/mTOR inhibitor, targets all class I PI3K isoforms plus mTORC1/2, which may better overcome resistance than single-node therapies and supports a broad HR+/HER2- franchise. The Phase 3 VIKTORIA-1 program has already met its primary endpoint in the PIK3CA mutant cohort, while cohort 2 and the ongoing VIKTORIA-2 and CELC-G-201 studies extend the opportunity into endocrine-resistant breast cancer and metastatic castration-resistant prostate cancer. Commercially, the company has announced a $10,000 vial price, about $30,000 per cycle, expects roughly an 80% gross-to-net, has coverage across more than 90% of medical-benefit lives, and is preparing for late 3Q26 launches with an expanded access program already shipping.

Celcuity is a high-risk clinical-stage biotech whose outlook is pressured by the possibility that gedatolisib may fail to show sufficient efficacy or safety in current or future trials, despite its broad PAM-pathway mechanism. Approval and commercialization remain uncertain because the company still depends on FDA and foreign regulatory clearances, while the HR+ mBC market is already crowded with better-resourced competitors that could limit adoption or delay progress. Financially, the company may need additional equity financing to fund development, which would likely dilute existing shareholders, and the key downside remains failure to win approval, further regulatory delays, or inability to raise enough capital.